Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 3/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL28720905 | 0.88 | CACNA1C (0.39) | CACNA1CSCN5AKCNH2ELANEKDM4C | |
| SCHEMBL4113139 | 0.85 | ELANE (0.43) | ELANEHCAR3ALDH1A1CA1CA2 | |
| Triphosphate SCHEMBL8441046 | 0.83 | P2RY2 (0.35) | CACNA1CSCN5AKCNH2ELANEHCAR3 | |
| SCHEMBL29509040 | 0.82 | TLR8 (0.49) | ELANEHCAR3ALDH1A1CA1CA2 | |
| SCHEMBL606375 | 0.80 | ELANE (0.46) | ELANEHCAR3CNR1 | |
| SCHEMBL19692262 | 0.80 | ALDH1A1 (0.33) | ADORA2AADORA1ALDH1A1POLB | |
| SCHEMBL236001 | 0.80 | ALDH1A1 (0.33) | ADORA2AADORA1ALDH1A1POLB | |
| SCHEMBL17372301 | 0.80 | ALDH1A1 (0.33) | ADORA2AADORA1ALDH1A1POLB | |
| SCHEMBL30688742 | 0.79 | ESR1 (0.46) | HCAR3 | |
| SCHEMBL18660242 | 0.79 | KCNH3 (0.36) | ADORA2AADORA1ALDH1A1POLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1717 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106907-A1 | FAST PCR BY TANDEM PRIMER EMBEDDED WITH RIBONUCLEOTIDE | CEPHEID (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260117214-A1 | Prime Editing Systems having pegRNA with Reduced Auto-inhibitory Interaction | UNIV MASSACHUSETTS (US) | 2026-04-30 | — | — | US | claimed |
| EP-4689099-A1 | PRIME EDITING SYSTEMS HAVING PEGRNA WITH REDUCED AUTO-INHIBITORY INTERACTION | University of Massachusetts (US) | 2026-02-11 | — | — | EP | claimed |
| US-12460256-B1 | Nucleotide analogs for efficient DNA and RNA amplification | BENNER STEVEN A (US) | 2025-11-04 | — | — | US | claimed |
| EP-4558641-A1 | METHODS FOR DETECTION AND REDUCTION OF SAMPLE PREPARATION-INDUCED METHYLATION ARTIFACTS | Guardant Health, Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2025-02-27 | — | — | US | claimed |
| WO-2024220135-A1 | PRIME EDITING SYSTEMS HAVING PEGRNA WITH REDUCED AUTO-INHIBITORY INTERACTION | UNIVERSITY OF MASSACHUSETTS (US) | 2024-10-24 | — | — | WO | claimed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| WO-2024020573-A1 | METHODS FOR DETECTION AND REDUCTION OF SAMPLE PREPARATION-INDUCED METHYLATION ARTIFACTS | GUARDANT HEALTH, INC. (US) | 2024-01-25 | — | — | WO | claimed |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | HYBRIDON, INC. | 2004-05-20 | — | — | US | claimed |
| JP-2004509970-A | — | — | 2004-04-02 | — | — | JP | claimed |
| EP-1393745-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends | HYBRIDON, INC. (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2004016805-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-02-26 | — | — | WO | claimed |
| WO-2003057822-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| EP-1322656-A2 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | HYBRIDON, INC. (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2003035836-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY OPTIMAL PRESENTATION OF 5' ENDS | HYBRIDON INC. (US) | 2003-05-01 | — | — | WO | claimed |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | IDERA PHARMACEUTICALS, INC | 2002-09-26 | — | — | US | claimed |
| WO-2002026757-A2 | MODULATION OF IMMUNOSTIMULATORY ACTIVITY OF IMMUNOSTIMULATORY OLIGONUCLEOTIDE ANALOGS BY POSITIONAL CHEMICAL CHANGES | HYBRIDON, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| WO-1998000564-A1 | METHODS AND COMPOSITIONS FOR SEQUENCE-SPECIFIC HYBRIDIZATION OF RNA BY 2'-5' OLIGONUCLEOTIDES | DYAD PHARMACEUTICAL CORPORATION (US) | 1998-01-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117214-A1 | Prime Editing Systems having pegRNA with Reduced Auto-inhibitory Interaction | SSU72, ADAR, UPF1 | CACNA1C 4804/4885SCN5A 3982/4885KCNH2 4862/4885 |
| US-20250066799-A1 | UNNATURAL BASE PAIR COMPOSITIONS AND METHODS OF USE | RNGTT, SPOUT1, NPEPPS | CACNA1C 4721/4885SCN5A 4215/4885KCNH2 4315/4885 |
| US-20020137714-A1 | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes | STING1, IRF3, TLR9 | CACNA1C 4834/4885SCN5A 4292/4885KCNH2 4674/4885 |
| US-20040097719-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends | TLR5, TLR3, ENTPD5 | CACNA1C 4856/4885SCN5A 2047/4885KCNH2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.